{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pad:pad-024-drug-coated-balloon",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent"
    ],
    "confidence": 0.95,
    "status": "enhanced",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pad",
    "type": "endovascular-technique",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "PAD-024",
    "keywords": [
      "drug-coated balloon",
      "DCB",
      "paclitaxel",
      "femoropopliteal",
      "restenosis prevention"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "lower_extremity_arterial_disease",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Drug-Coated Balloon Therapy in Peripheral Arterial Disease",
    "statement": "Drug-Coated Balloon Therapy in Peripheral Arterial Disease is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Pad that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Drug-Coated Balloon Therapy in Peripheral Arterial Disease helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Drug-Coated Balloon Therapy in Peripheral Arterial Disease include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Drug-Coated Balloon Therapy in Peripheral Arterial Disease."
    },
    "mechanism": {
      "drug": {
        "agent": "Paclitaxel",
        "mechanism": "Microtubule stabilization, inhibits cell division",
        "dose": "2-3.5 \u03bcg/mm\u00b2 balloon surface",
        "local_effect": "Inhibits smooth muscle proliferation"
      },
      "excipient": {
        "purpose": "Facilitates drug transfer from balloon to vessel wall",
        "types": [
          "Urea",
          "Shellac",
          "Butyryl tri-hexyl citrate",
          "Polysorbate/sorbitol"
        ],
        "importance": "Affects drug bioavailability and clinical outcomes"
      },
      "delivery": {
        "inflation_time": "60-180 seconds",
        "sizing": "1:1 ratio with reference vessel diameter",
        "pressure": "Nominal pressure usually sufficient"
      }
    },
    "clinical_applications": {
      "femoropopliteal_disease": {
        "indication": "Primary treatment or after vessel preparation",
        "evidence": "Multiple RCTs show superiority over POBA",
        "lesion_length": "Effective up to 20-25 cm lesions"
      },
      "post_atherectomy": {
        "rationale": "Prepared vessel bed improves drug uptake",
        "evidence": "DEFINITIVE AR and other studies support combination"
      },
      "in_stent_restenosis": {
        "indication": "Treatment of failed prior stent",
        "evidence": "FAIR and ISAR-PEBIS trials show benefit"
      },
      "tibial_disease": {
        "evidence": "More limited, ongoing trials",
        "consideration": "Smaller vessels, different disease pattern"
      }
    },
    "vessel_preparation": {
      "importance": "Critical for optimal DCB outcomes",
      "techniques": [
        "Predilation with undersized balloon",
        "Scoring/cutting balloon for resistant lesions",
        "Atherectomy for heavily calcified lesions",
        "Intravascular lithotripsy for calcium modification"
      ],
      "goal": "<30% residual stenosis before DCB application"
    },
    "outcomes_data": {
      "primary_patency": {
        "one_year": "70-85%",
        "two_year": "60-75%"
      },
      "target_lesion_revascularization": {
        "one_year": "10-20%"
      },
      "vs_poba": {
        "restenosis_reduction": "30-50% relative reduction"
      }
    },
    "safety_considerations": {
      "paclitaxel_mortality_signal": {
        "background": "2018 meta-analysis suggested increased mortality",
        "subsequent_analyses": "Patient-level data analyses showed no significant difference",
        "current_status": "DCBs remain approved and widely used",
        "guidance": "Appropriate patient selection and informed consent"
      },
      "contraindications": [
        "Significant dissection requiring stent",
        "Acute limb ischemia with thrombus",
        "Severely calcified lesions without preparation"
      ]
    },
    "terminology": {
      "snomed_ct": "698356008",
      "icd_10": "Z95.828"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Drug-Coated Balloon in PAD"
    },
    "altLabel": [
      "DCB",
      "Paclitaxel-Coated Balloon",
      "Drug-Eluting Balloon"
    ],
    "definition": {
      "@language": "en",
      "@value": "Angioplasty balloon technology that delivers antiproliferative medication to the vessel wall to reduce restenosis."
    },
    "notation": "PAD-024"
  },
  "clinical_features": {
    "presentation": [
      "Femoropopliteal claudication or CLTI",
      "In-stent restenosis",
      "Post-atherectomy adjunctive therapy"
    ],
    "diagnosis": [
      "Angiographic lesion assessment",
      "IVUS/OCT for calcium and vessel sizing",
      "Duplex for surveillance"
    ],
    "treatment": [
      "Vessel preparation (predilation or atherectomy)",
      "DCB application with 60-180 second inflation",
      "1:1 sizing with reference vessel",
      "Dual antiplatelet therapy post-procedure"
    ]
  },
  "relationships": {
    "prerequisites": [
      "vascular:pad:angioplasty-basics",
      "vascular:endovascular:balloon-angioplasty"
    ],
    "enables": [
      "vascular:pad:restenosis-prevention",
      "vascular:pad:limb-salvage"
    ],
    "skos:broader": [
      "vascular:pad:endovascular-techniques"
    ],
    "skos:related": [
      "vascular:pad:pad-025-des",
      "vascular:pad:pad-029-atherectomy"
    ],
    "skos:narrower": []
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Drug-Coated Balloon Therapy in Peripheral Arterial Disease. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "interventional radiology fellows",
      "interventional cardiology fellows"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "Explain the mechanism of drug-coated balloon therapy",
      "Identify appropriate indications for DCB use in PAD",
      "Describe optimal vessel preparation techniques before DCB",
      "Discuss the paclitaxel mortality controversy and current evidence"
    ],
    "clinical_pearls": [
      "Vessel preparation is critical - predilate to <30% residual stenosis before DCB",
      "Inflation time matters - 60-180 seconds for optimal drug transfer",
      "Size 1:1 with reference vessel, not lesion diameter",
      "DCBs preserve future surgical options by leaving nothing behind",
      "Dual antiplatelet therapy for 1-3 months post-procedure"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "698356008",
      "codingSystem": "SNOMED-CT",
      "name": "Drug-coated balloon angioplasty"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "37224",
      "codingSystem": "CPT",
      "name": "Transluminal peripheral angioplasty, femoral/popliteal"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "C2623",
      "codingSystem": "HCPCS",
      "name": "Drug-coated balloon catheter"
    }
  ]
}